|
Malignant neoplasm of stomach
|
0.340 |
Biomarker
|
disease |
BEFREE |
We found EMT in gastric cancer cell lines that underwent α-thrombin-induced PAR1 activation.
|
25231630 |
2014 |
|
Malignant neoplasm of stomach
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
PAR-1 IVSn-14 T allele is a risk factor for H. pylori-related GC in ethnic Chinese subjects.
|
22993310 |
2012 |
|
Malignant neoplasm of stomach
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1).
|
21966428 |
2011 |
|
Malignant neoplasm of stomach
|
0.340 |
Biomarker
|
disease |
BEFREE |
Thus, PAR1 is a potentially important therapeutic target for the treatment of gastric cancer.
|
20723226 |
2010 |
|
Malignant neoplasm of stomach
|
0.340 |
Biomarker
|
disease |
CTD_human |
Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.
|
16367923 |
2006 |
|
Fibrosis, Liver
|
0.320 |
Biomarker
|
disease |
BEFREE |
We tested the hypothesis that tissue factor (TF)-dependent thrombin generation and protease activated receptor-1 (PAR-1) activation contribute to liver fibrosis induced by cholestasis via induction of αVβ6 expression.
|
21037076 |
2010 |
|
Fibrosis, Liver
|
0.320 |
Biomarker
|
disease |
CTD_human |
Similarly, liver fibrosis was significantly reduced in PAR-1(-/-) mice fed an ANIT diet.
|
21037076 |
2010 |
|
Fibrosis, Liver
|
0.320 |
Biomarker
|
disease |
BEFREE |
Inhibition of thrombin receptor protease-activated receptor 1 (PAR-1) has been shown to reduce liver fibrosis in animals.
|
18005014 |
2008 |
|
Inflammation
|
0.310 |
Biomarker
|
phenotype |
CTD_human |
Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice.
|
20008134 |
2010 |
|
Liver Cirrhosis
|
0.310 |
Biomarker
|
disease |
CTD_human |
The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis.
|
21037076 |
2010 |
|
Liver Cirrhosis
|
0.310 |
GeneticVariation
|
disease |
LHGDN |
Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis.
|
18005014 |
2008 |
|
Inflammation
|
0.310 |
Biomarker
|
phenotype |
LHGDN |
Thus, trypsin IV and p23 are inhibitor-resistant trypsins that can cleave and activate PARs, causing PAR(1)- and PAR(2)-dependent inflammation and PAR(2)-dependent hyperalgesia.
|
17623652 |
2007 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Fatty Liver
|
0.300 |
Biomarker
|
disease |
CTD_human |
Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.
|
22841818 |
2012 |
|
Steatohepatitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Deficiency in the thrombin receptor protease activated receptor-1 reduces hepatic inflammation and steatosis in mice fed a Western diet.
|
22841818 |
2012 |
|
Fatty Liver
|
0.300 |
Biomarker
|
disease |
CTD_human |
Using an established mouse model of Western diet-induced NAFLD, we tested whether the thrombin receptor protease-activated receptor 1 (PAR-1) and hematopoietic cell-derived tissue factor (TF) contribute to hepatic steatosis.
|
21907177 |
2011 |
|
Hepatitis
|
0.300 |
Biomarker
|
group |
CTD_human |
These studies indicate that PAR-1 and hematopoietic cell TF are required for liver inflammation and steatosis in mice fed a Western diet.
|
21907177 |
2011 |
|
Steatohepatitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Similar to PAR-1 deficiency, hematopoietic cell TF deficiency was associated with reduced inflammation and reduced steatosis in livers of low-density lipoprotein receptor-deficient mice fed a Western diet.
|
21907177 |
2011 |
|
Fatty Liver
|
0.300 |
Biomarker
|
disease |
CTD_human |
Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice.
|
20008134 |
2010 |
|
Steatohepatitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
We tested the hypothesis that tissue factor (TF)-dependent thrombin generation and the thrombin receptor protease activated receptor-1 (PAR-1) contribute to liver inflammation induced by steatosis in mice.
|
20008134 |
2010 |
|
Neoplasms, Experimental
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression.
|
17374729 |
2007 |
|
Stomach Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.
|
16367923 |
2006 |
|
Hereditary Diffuse Gastric Cancer
|
0.300 |
Biomarker
|
disease |
CTD_human |
Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.
|
16367923 |
2006 |
|
Hyperalgesia
|
0.220 |
Biomarker
|
phenotype |
BEFREE |
Blocking either spinal thrombin or PAR1 completely prevented compression-induced hyperalgesia for 7 days.
|
28059686 |
2017 |
|
Hyperalgesia
|
0.220 |
Biomarker
|
phenotype |
LHGDN |
Thus, trypsin IV and p23 are inhibitor-resistant trypsins that can cleave and activate PARs, causing PAR(1)- and PAR(2)-dependent inflammation and PAR(2)-dependent hyperalgesia.
|
17623652 |
2007 |